References
- Hoadley J. Cost containment strategies for prescription drugs: assessing the evidence in the literature. Kaiser Family Foundation, 2005. Available at: https://kaiserfamilyfoundation.files.wordpress.com/2013/01/cost-containment-strategies-for-precription-drugs-assessing-the-evidence-in-the-literature-report.pdf
- The Kaiser Family Foundation and HRET (Health Research and Educational Trust). Employer Health Benefits 2014 Annual Survey. 2014. Available at: http://files.kff.org/attachment/2014-employer-health-benefits-survey-full-report. Accessed March 2015
- Gemmill MC, Thomson S, Mossialos E. What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries. Int J Equity Health 2008;7:12
- Fairman KA, Motheral BR, Henderson RR. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Therapeut 2003;25:3147-61; discussion 4–6
- Rector TS, Finch MD, Danzon PM, et al. Effect of tiered prescription copayments on the use of preferred brand medications. Med Care 2003;41:398-406
- Nair KV, Wolfe P, Valuck RJ, et al. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. JMCP 2003;9:123-33
- Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. New Engl J Med 2003;349:2224-32
- Hodgkin D, Parks Thomas C, Simoni-Wastila L, et al. The effect of a three-tier formulary on antidepressant utilization and expenditures. j Ment Health Policy Econ 2008;11:67-77
- Gleason PP, Gunderson BW, Gericke KR. Are incentive-based formularies inversely associated with drug utilization in managed care? Ann Pharmacother 2005;39:339-45
- Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007;298:61-9
- Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care 2005;11:730-40
- Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004;291:2344-50
- Mann BS, Barnieh L, Tang K, et al. Association between drug insurance cost sharing strategies and outcomes in patients with chronic diseases: a systematic review. PloS One 2014;9:e89168
- Austvoll-Dahlgren A, Aaserud M, Vist G, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane database System Rev 2008;(1):CD007017
- CDC. 2014 National Diabetes Fact Sheet. Atlanta, GA: CDC, 2014
- Christian-Herman J, Emons M, George D. Effects of generic-only drug coverage in a Medicare HMO. Health affairs (Project Hope). 2004;(Suppl Web Exclusives):W4-455-68. doi: 10.1377/hlthaff.w4.455
- Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care 2005;43:951-9
- Colombi AM, Yu-Isenberg K, Priest J. The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. J Occupat Environ Med Am Coll Occupat Environl Med 2008;50:535-41
- Sacks NC, Burgess JF Jr, Cabral HJ, et al. Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries. J Gen Intern Med 2013;28:876-85
- Bridge to Data: Optum Insights Clinformatics Data Mart. 2015. Available at: http://www.bridgetodata.org. Accessed March 20, 2015
- Kleinrock M. The use of medicines in the United States: Review of 2011. New Jersey: IMS Institute for Healthcare Informatics, 2012 . Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf
- Piette JD, Wagner TH, Potter MB, et al. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care 2004;42:102-9
- Heisler M, Langa KM, Eby EL, et al. The health effects of restricting prescription medication use because of cost. Med Care 2004;42:626-34
- Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care 2005;11(Suppl 5):S170-6